Switching from low-dose thiazide diuretics to sodium–glucose cotransporter 2 inhibitor improves various metabolic parameters without affecting blood pressure in patients with type 2 diabetes and hypertension

Tomohiko Kimura1*, Junpei Sanada1, Masashi Shimoda1, Hidenori Hirukawa1, Yoshiro Fushimi1, Momoyo Nishioka1, Tomoe Kinoshita1, Seizo Okauchi1, Atsushi Obata1, Kenji Kohara1, Fuminori Tatsumi1, Shinji Kamei1, Shuhei Nakanishi1, Tomoatsu Mune1, Kohei Kaku2, Hideaki Kaneto1

1Division of Diabetes, Endocrinology and Metabolism, Kawasaki Medical School, Kurashiki, and 2Department of General Internal Medicine 1, Kawasaki Hospital, Kawasaki Medical School, Okayama, Japan

Keywords
Hypertension, Sodium–glucose cotransporter inhibitor, Thiazide diuretics

*Correspondence
Tomohiko Kimura
Tel.: +81-86-462-1111
Fax: +81-86-464-1046
E-mail address: tomohiko@med.kawasaki-m.ac.jp

J Diabetes Investig 2018; 9: 875–881
doi: 10.1111/jdi.12774

Clinical Trial Registry
University Hospital Medical Information Network
UMINR000033348

ABSTRACT

Aims/Introduction: Sodium–glucose cotransporter 2 (SGLT2) inhibitors function to increase urinary glucose excretion and improve glycemic control in individuals with type 2 diabetes mellitus. SGLT2 inhibitors, as well as diuretics, increase urinary volume, which leads to the reduction of blood pressure. The aim of the present study was to compare the effects of SGLT2 inhibitor and thiazide diuretic on blood pressure, metabolic parameters and body mass composition.

Materials and Methods: A total of 31 participants were enrolled in the present study. We switched from thiazide diuretics to an SGLT2 inhibitor, ipragliflozin, in participants with type 2 diabetes and hypertension whose blood pressure was controlled with thiazide diuretics. Three months after the switch, we evaluated the effects of such switching on blood pressure, various metabolic parameters and body mass composition.

Results: There was no significant difference in blood pressure from baseline to 3 months later. However, glycated hemoglobin, fasting plasma glucose and uric acid were significantly decreased after the switch. Body mass index and visceral fat area were also significantly reduced after the switch. Furthermore, urinary albumin excretion was also significantly decreased after the switch.

Conclusions: Switching from thiazide diuretic to an SGLT2 inhibitor, ipragliflozin, markedly improved various metabolic parameters and body mass composition without affecting blood pressure in participants with type 2 diabetes and hypertension.
calcium channel blockers (CCBs) or a small amount of thiazide diuretic is recommended as a next step. CCB has a relatively strong blood pressure-lowering effect and reduces the risk of cardiovascular disease. It has been reported that thiazide diuretics decrease cardiovascular events. However, thiazide diuretics worsen glucose and lipid metabolism, and they cause hypokalemia, hypomagnesemia and hyperuricemia. Some reports showed that thiazide diuretics did not decrease cardiovascular events because of exacerbated glucose and lipid metabolism.

Sodium–glucose cotransporter 2 (SGLT2) inhibitor is a novel class of oral anti-hyperglycemic drug. SGLT2 is expressed primarily in the S1 segment of the proximal tubule and accounts for approximately 90% of reabsorbed glucose. Treatment with SGLT2 inhibitor leads to improved glycemic control, caloric loss and reduced bodyweight through an insulin-independent manner. This causes an osmotic diuresis and mild natriuresis, which leads to the reduction in plasma volume and visceral fat mass reduction, and the decrease of blood pressure. Clinical trials have shown a significant reduction from baseline in both systolic and diastolic blood pressure after administration of SGLT2 inhibitors. Although the blood pressure-lowering effects of SGLT2 inhibitors are already established, guidance is required on how to use these agents in patients already receiving the most commonly prescribed antihypertensive regimens.

In the present study, we switched from thiazide diuretics to an SGLT2 inhibitor, ipraglirozin, in participants with type 2 diabetes and hypertension whose blood pressure was controlled with thiazide diuretics, and evaluated the effects of such switching on blood pressure, glycemic control, other metabolic parameters and body mass composition.

**METHODS**

**Study population and patient preparation**

The present study was retrospectively carried out with outpatients in the division of Diabetes, Endocrinology and Metabolism in Kawasaki Medical School from January to September in 2016. Enrolled patients met the following criteria: (i) glycated hemoglobin (HbA1c)>6.0%; and (ii) having already taken thiazide diuretics for hypertension with ARB or angiotensin-converting enzyme inhibitors and/or CCB in participants with type 2 diabetes. In addition, the participants were those who fulfilled the following criteria: (i) without severe renal dysfunction; (ii) without severe liver dysfunction; (iii) without infectious disease, malignancy or various endocrine diseases; and (iv) not using steroid drugs. We switched from only thiazide diuretics to 50 mg of the SGLT2 inhibitor, ipraglirozin. We compared the blood pressure, metabolic parameters and body composition using InBody770 (InBody Japan, Tokyo, Japan) before and after 3 months from switching. A total of 31 (22 men, 9 women) participants were enrolled in the present study. As it is well known that blood pressure is substantially influenced by temperature, and that there is seasonal variation in HbA1c levels, as a control we used the data of individuals (n = 19) who used thiazide diuretics as an antihypertensive drug, but did not switch to an SGLT2 inhibitor in the same observation period as the switching group. In addition, the start month ratio of the non-switching group corresponded to that of the switching group using a random number table in order to avoid the possible influence of other factors. The registration number of UMIN was R000033348. The study protocol was approved by the institutional review board of Kawasaki Medical School (No. 2540), and the study was carried out in accordance with the Declaration of Helsinki, and we provided public information on the study via the Internet, instead of obtaining informed consent from each patient. We carried out data collection for variables such as type of medication and smoking status, as well as biochemical data.

**Statistical analysis**

All analyses were carried out by using JMP version 9 (SAS Institute Inc., Cary, NC, USA). The paired t-test and Wilcoxon signed-rank test were used for the comparison between two paired groups. Student’s t-test and Mann–Whitney U-tests were used for the difference between the switching group and non-switching group with P < 0.05 regarded as significant. The results were expressed as mean ± standard deviation. To examine which factors are associated with change in (∆) blood pressure, we carried out Spearman’s rank correlation coefficient test. Furthermore, to examine which factors independently determine ∆blood pressure, we carried out multiple regression analysis.

**RESULTS**

**Clinical characteristics in the study participants**

A total of 31 (22 men, 9 women) participants were enrolled in the present study. The characteristics of the study participants at baseline were as follows: age 68.9 ± 8.5 years old; body mass index (BMI) 27.7 ± 5.2 kg/m²; duration of diabetes 16.2 ± 9.4 years; HbA1c 7.1 ± 1.0%; and fasting plasma glucose 141.2 ± 42.8 mg/dL. The frequencies of diabetic complications were as follows: neuropathy 51.6%; retinopathy 19.4%; and nephropathy (urinary albumin ≥30 mg/gCr) 51.6%. The frequencies of ischemic heart disease and stroke were 3.2 and 19.4%, respectively. The insulin and glucagon-like peptide-1 receptor agonist usage rate were both 9.7%, and usage rate of dipeptidyl peptidase-4 inhibitor, metformin, thiazolidine, sultfonylurea, glinide and α-glucosidase inhibitor were 58.1, 64.5, 54.8, 29.3, 12.9 and 16.1%, respectively. The usage rate of angiotensin receptor blocker, calcium channel blocker, statin, fibrates and antihyperuricemics were 96.8, 71.0, 58.1, 12.9, and 12.9%, respectively. The breakdown and dosage of the thiazide diuretics were hydrochlorothiazide (67.7%, 7.7 ± 2.7 mg), indapamide (22.6%, 0.9 ± 0.2 mg) and trichlormethiazide (9.7%, 1.3 ± 0.6 mg). The ARB and CCB usage rates were 96.8 and 71.0%, respectively, and there were no dosage changes in any drugs for 3 months after switching.
Evaluation of various metabolic parameters after switching from thiazide diuretics to SGLT2 inhibitor ipragliflozin

The differences in all parameters from baseline to 3 months later are shown in Table 1. Surprisingly, 3 months after the switch, the mean systolic and diastolic blood pressure did not significantly change from baseline (from 131.2 ± 13.2 mmHg to 132.1 ± 13.2 mmHg; from 74.5 ± 9.9 mmHg to 75.8 ± 11.2 mmHg). Heart rate also did not change from baseline to 3 months later (from 71.0 ± 16.3 b.p.m. to 68.0 ± 11.8 b.p.m.; Table 1). HbA1c and fasting blood glucose levels were significantly improved 3 months later compared with baseline (from 7.1 ± 1.0% to 6.7 ± 0.9%, P < 0.0001; from 141.2 ± 42.8 mg/dL to 118.9 ± 26.5 mg/dL, P < 0.005), and fasting insulin level was significantly reduced 3 months later compared with baseline (from 8.1 ± 5.5 μU/mL to 6.4 ± 4.4 μU/mL, P < 0.01). We believe that such phenomena were due to the increase of urinary glucose excretion by ipragliflozin, which led to the decline of insulin demand. A significant reduction was observed in BMI (from 27.7 ± 5.2 kg/m² to 27.2 ± 5.2 kg/m², P < 0.005). Switching from thiazides to an SGLT2 inhibitor also resulted in improvement of lipid profile. High-density lipoprotein cholesterol was significantly increased 3 months later compared with baseline (from 51.6 ± 13.8 kg/m² to 55.8 ± 15.9 kg/m², P < 0.05). In contrast, there were no significant changes in low-density lipoprotein cholesterol and triglyceride from baseline to 3 months later (from 42.8 mg/dL to 41.7 mg/dL, NS).

Table 1 | Comparison of various values between at baseline and 3 months later in the switching and non-switching group

| Parameter                          | Baseline | 3 months |
|------------------------------------|----------|----------|
|                                    | Switching: A | Non-switching: B | P (A vs B) | Switching: C | Non-switching: D | P (C vs D) | P (A vs C) | P (B vs D) |
| Age (years)                        | 68.1 ± 8.5 | 70.5 ± 8.9 | NS         | -           | -           | -           | -         | -         |
| DM duration (years)                | 162 ± 9.4 | 192 ± 10.2 | NS         | -           | -           | -           | -         | -         |
| BMI (kg/m²)                        | 27.7 ± 5.2 | 25.9 ± 3.9 | NS         | -           | -           | -           | -         | -         |
| Bodyweight (kg)                    | 74.5 ± 19.4 | 66.1 ± 9.4 | NS         | -           | -           | -           | -         | -         |
| HR (b.p.m.)                        | 71.0 ± 16.3 | 71.3 ± 13.6 | NS         | -           | -           | -           | -         | -         |
| SBP (mmHg)                         | 131.2 ± 12.9 | 134.7 ± 14.7 | NS         | -           | -           | -           | -         | -         |
| DBP (mmHg)                         | 74.5 ± 9.9 | 71.1 ± 8.7 | NS         | -           | -           | -           | -         | -         |
| Hemoglobin (g/dL)                  | 39.1 ± 4.3 | 400.4 ± 47 | NS         | -           | -           | -           | -         | -         |
| HbA1c (%)                          | 7.1 ± 1.0 | 6.6 ± 0.6 | <0.05      | -           | -           | -           | -         | -         |
| FPG (mg/dL)                        | 141.2 ± 42.8 | -           | -           | -           | -           | -           | -         | -         |
| Insulin (μU/mL)                    | 8.1 ± 5.5 | -           | -           | -           | -           | -           | -         | -         |
| Serum Na (mEq/L)                   | 139.5 ± 2.1 | 138.6 ± 1.8 | NS         | -           | -           | -           | -         | -         |
| Serum K (mEq/L)                    | 4.2 ± 0.3 | 4.2 ± 0.3 | NS         | -           | -           | -           | -         | -         |
| UA (mg/dL)                         | 60.1 ± 1.3 | 57.1 ± 1.3 | NS         | -           | -           | -           | -         | -         |
| Cre (mg/dL)                        | 0.8 ± 0.2 | 0.8 ± 0.2 | NS         | -           | -           | -           | -         | -         |
| BUN (mg/dL)                        | 183.5 ± 5.3 | 186.6 ± 69 | NS         | -           | -           | -           | -         | -         |
| eGFR (ml/min/1.73 m²)              | 67.9 ± 14.4 | 67.3 ± 224 | NS         | -           | -           | -           | -         | -         |
| LDL-C (mg/dL)                      | 92.0 ± 23.6 | 845.5 ± 241 | NS         | -           | -           | -           | -         | -         |
| HDL-C (mg/dL)                      | 516.3 ± 138 | 538.2 ± 168 | NS         | -           | -           | -           | -         | -         |
| TG (mg/dL)                         | 1028 ± 514 | -           | -           | -           | -           | -           | -         | -         |
| Ketone body (μmol/L)               | 222.1 ± 2340 | -           | -           | -           | -           | -           | -         | -         |
| Urinalysis                          | Switching (baseline) | Switching (3 months) | P-value |
| Urinary Na (mEq/L)                 | 1206.1 ± 423 | 1146.1 ± 33.5 | NS         |
| Urinary Alb (mg/gCr)               | 165.2 ± 335 | 1088.2 ± 190.4 | <0.05      |
| Urinary NAG (IU/L)                 | 129.1 ± 14.1 | 86.5 ± 58 | <0.05      |
| Urinary glucose (mg/dL)            | 1128 ± 330.5 | 26240.0 ± 14194 | <0.0001    |
| InBody                              | Switching (baseline) | Switching (3 months) | P-value |
| Body fat mass (kg)                 | 25.5 ± 12.1 | 24.4 ± 12.4 | <0.0005    |
| Visceral fat area (cm²)            | 121.1 ± 51.4 | 115.5 ± 49.6 | <0.005     |
| Skeletal muscle mass (kg)          | 26.9 ± 6.2 | 268.6 ± 64 | NS         |

Data presented as mean ± standard deviation. BMI, body mass index; DBP, diastolic blood pressure; DM, diabetes mellitus; eGFR, estimated glomerular filtration rate; HDL-C, high-density lipoprotein cholesterol; HR, heart rate; LDL-C, low-density lipoprotein cholesterol; K, potassium; Na, sodium; NAG, N-acetyl-β-D-glucosaminidase; NS, not significant; SBP, systolic blood pressure; TG, triglyceride; UA, uric acid.
92.0 ± 23.6 mg/dL to 92.4 ± 23.5 mg/dL; from 102.8 ± 51.4 mg/dL to 89.5 ± 47.1 mg/dL). Furthermore, the dramatic improvement was observed in uric acid levels after the switching from thiazides diuretics to an SGLT2 inhibitor (from 6.0 ± 1.3 mg/dL to 5.0 ± 1.1 mg/dL, P < 0.0001). Amazingly, the amount of urinary sodium excretion was kept at the same level despite switching from thiazides diuretics (from 120.6 ± 42.3 mEq/L to 114.6 ± 33.5 mEq/L, not significant). The switching from thiazide diuretics to iragliflozin led to the significant reduction of urinary albumin excretion (from 165.2 ± 335.5 mg/gCr to 108.8 ± 190.4 mg/gCr, P < 0.05).

Urinary N-acetyl-b-D-glucosaminidase was also significantly reduced from 12.9 ± 14.1 U/L to 8.6 ± 5.8 U/L during 3 months (P < 0.05). Ketone bodies did not increase significantly after the switch (from 222.1 ± 234.0 μmol/L to 292.0 ± 138.2 μmol/L).

Evaluation of body mass composition after switching from thiazide diuretics to SGLT2 inhibitor iragliflozin

In order to examine the change in body composition when switching from thiazide diuretics to iragliflozin, we investigated it using InBody770. A significant reduction of body fat mass and percentage were observed 3 months later after the switch compared with baseline (from 25.5 ± 12.1 kg to 24.4 ± 12.4 kg, P < 0.0005; from 32.8 ± 7.9% to 31.7 ± 8.3%, P < 0.005). It seemed that body fat reduction was due to the reduction of visceral fat mass (from 121.1 ± 51.4 cm² to 115.5 ± 49.6 cm², P < 0.005). In contrast, there was no difference in the skeletal muscle mass between before and after SGLT2 inhibitor administration (from 26.9 ± 6.2 kg to 26.8 ± 6.4 kg; Table 1).

Comparison of various parameters between switching group from thiazide diuretics to SGLT2 inhibitor iragliflozin and non-switching group

As a control, we used the data of participants (n = 19) who used thiazide diuretics as an antihypertensive drug without switching to SGLT2 inhibitor and did not change dosage in any other drugs in the same observation period as the switching group. First and most importantly, there were no significant differences in age and duration of diabetes between the switching group and non-switching group (Table 1). Next, there were no significant differences in Δsystolic and Δdiastolic blood pressure of the two groups (Table 2). These data show that the patients in both groups had similar characteristics. In addition, there was no significant difference in systolic blood pressure levels at baseline and 3 months later between the switching to SGLT2 inhibitor group and non-switching group (baseline 131.2 ± 12.9 mmHg vs 134.7 ± 14.7 mmHg; 3 months later 132.1 ± 13.2 mmHg vs 132.6 ± 18.8 mmHg). The same result was observed in diastolic blood pressure (baseline 74.5 ± 9.9 mmHg vs 71.1 ± 8.7 mmHg; 3 months later 75.8 ± 11.2 mmHg vs 69.7 ± 11.1 mmHg; Table 1). ΔHbA1c significantly decreased in the switching group compared with the non-switching group (P < 0.05; Table 1). Although the HbA1c level in the switching group at baseline was significantly higher than that of the non-switching group (7.1 ± 1.0% vs 6.6 ± 0.6%, P < 0.05), there was no significant difference at 3 months later between the two groups (6.7 ± 0.9% vs 6.5 ± 0.7%). Furthermore, in the non-switching group, there were no significant changes in blood pressure, HbA1c, fasting blood glucose and uric acid during 3 months corresponding to the follow-up period in the switching group.

In addition, to examine in which individuals the SGLT2 inhibitor effectively exerted an antihypertensive effect, we carried out univariate analyses. There was no significant correlation between Δblood pressure (both Δsystolic blood pressure and Δdiastolic blood pressure) and baseline values of BMI, body weight, visceral fat mass area, HbA1c, uric acid, age, sex and Δvisceral fat area, and ΔHbA1c and Δbody weight in the switching group (data not shown). Furthermore, to examine which factors contribute to the antihypertensive effect of SGLT2 inhibitors, we examined whether Δblood pressure was influenced by taking ARB, pioglitazone, glucagon-like peptide-1 receptor agonists, insulin and smoking. However, there was no significant correlation between them. In addition, there was no significant correlation between Δblood pressure and estimated salt intake, which was calculated with urinary Na excretion. We also examined whether Δblood pressure was influenced by the type and amount of thiazide diuretics, but there was no significant correlation between them (data not shown).

DISCUSSION

In the present study, we switched from thiazide diuretics to the SGLT2 inhibitor, iragliflozin, in participants with type 2 diabetes and hypertension. Three months after the switch, there was no significant difference in systolic and diastolic blood pressure from the baseline. Although it was known that SGLT2 inhibitors exerted beneficial effects on blood pressure, we believe that the data in the present study clearly show that there is no clear difference in blood pressure-lowering effects between thiazide diuretics and SGLT2 inhibitor. In this study, we encouraged the participants to measure blood pressure at home and obtained the data from 22 participants. Although there might be some problem in the point of accuracy in self-monitoring blood pressure, there was a significant improvement in the average systolic and diastolic blood pressure 3 months after the switch to iragliflozin (average from −1 month to baseline 135.8 ± 11.5 mmHg, 73.5 ± 9.9 mmHg, average from 1 month to 3 months: 129.5 ± 10.3 mmHg, 70.9 ± 9.3 mmHg, P < 0.05, P < 0.005, respectively). These self-monitoring blood pressure data, as well as the blood pressure data obtained in our hospital, show that the blood pressure-lowering effects of SGLT2 inhibitor are, at least, not weak compared with those of thiazide diuretics.

In the present study, we set a control group that did not change to iragliflozin from thiazide diuretics in order to exclude the influence of seasonal variation in various variables,
such as blood pressure and HbA1c level, as much as possible. In addition, the start month ratio of the non-switching group corresponded to that of the switching group using a random number table in order to avoid the possible influence of other factors. BMI and bodyweight were decreased in the non-switching group, as well as the switching group (Table 2). This was probably due to the fact that switching to ipragliozin mainly took place in winter, and thereby the season-matched control group was also allocated mainly in the winter season. Therefore, we cannot deny the possibility that BMI and bodyweight were decreased as a seasonal fluctuation due to change of lifestyle from winter to spring in the non-switching group.

Recently, it has been further established that SGLT2 inhibitors have the power to not only reduce blood pressure the same as thiazide diuretics, but also improve other metabolic parameters, such as high-density lipoprotein cholesterol and uric acid. Considering that the antihypertensive effect of thiazide diuretics is mainly based on the inhibition of Na+ reabsorption in the distal tubule, it was marvelous that the amount of urinary sodium excretion did not significantly change after switching to the SGLT2 inhibitor from thiazide diuretics. It was recently shown that the antihypertensive effect of SGLT2 inhibitor was considered to be, in large part, a loop diuretic effect. It is known that thiazide diuretics worsen glucose and lipid metabolism, but that SGLT2 inhibitors ameliorate glucose and lipid metabolism. Fasting insulin level was significantly reduced after the switch to ipragliozin. We believe that the main reason for the reduction of insulin secretion is the decline of insulin demand as a result of the marked increase of urinary glucose excretion by ipragliozin. In addition, the serum potassium level was slightly, but significantly, increased after switching from thiazide diuretics to ipragliozin. Therefore, although speculative, we believe it is possible that such an increase of serum potassium level was also involved in an increment of insulin secretion. We believe that such characteristics of these drugs contributed to the difference in the effects on various metabolic parameters. Taken together, it is likely that the switch from thiazide diuretics to SGLT2 inhibitor would improve various metabolic parameters without affecting blood pressure.

In addition, the switch from thiazide diuretics to an SGLT2 inhibitor, ipragliozin, led to the reduction of body mass index and visceral fat area. It is well known that visceral fat secretes various inflammatory cytokines, and is very closely associated with the development of insulin resistance and glucose intolerance. In addition, it is known that SGLT2 inhibitors function to alter body mass composition and reduce visceral fat mass. We believe that such reduction of visceral fat mass contributed to the amelioration of glycemic control after the switch to ipragliozin.

Furthermore, the switch from thiazide diuretics to an SGLT2 inhibitor, ipragliozin, led to the reduction of urinary albumin and urinary N-acetyl-β-D-glucosaminidase excretion, which are known as markers for proximal tubular disorder. Much attention has recently been drawn to SGLT2 inhibitors exerting beneficial effects on renal function as well, although the precise mechanism remains unclear. However, as a part of the possible mechanism, it is considered that SGLT2 inhibitors suppress glucose reabsorption with NaCl at the proximal tubule, which leads to the increment of NaCl at the distal tubule and the decline of glomerulus internal pressure through improvement of afferent arteriole expansion. In addition, ARB expands the efferent arteriole more than the afferent arteriole, which leads to kidney function protection. For these reasons, we believe that combined use of a SGLT2 inhibitor and ARB would lead to further protection of renal function, although some clinical studies with larger numbers of participants would be necessary to strengthen this hypothesis. It is obviously very important to prevent various diabetic complications, such as diabetic nephropathy, and urinary albumin excretion is an established marker of diabetic nephropathy. Therefore, we believe that the reduction of proximal tubular disorder markers after the switch from thiazide diuretics to ipragliozin would be very promising when we consider treatment for patients with type 2 diabetes and hypertension.

The data in the present study suggest that in patients with type 2 diabetes and hypertension using thiazide diuretics, it would be better to switch from thiazide diuretics to an SGLT2 inhibitor. It is likely that the switch from thiazide diuretics to an SGLT2 inhibitor would improve various metabolic parameters and body mass composition without affecting blood pressure. However, there were some limitations to the present study. First, this study had a small population. It was mainly because there were just 59 patients using thiazide diuretics for antihypertension, although >2,500 type 2 diabetes patients were treated in our hospital. It was thought that the attending doctors felt there could be potential problems of thiazide diuretics in view of patients’ metabolism. Second, this research was a retrospective study, and we could not set the control in the accurate meaning. However, as a control, we used the data of participants who used thiazide diuretics as an antihypertensive drug without switching to an SGLT2 inhibitor, and did not change the dosage in any other drugs in the same observation period as the switching group. Indeed, there was no substantial

Table 2 | Comparison of the change amount for 3 months between the switching group and non-switching group.

| Parameter               | Switching group | Non-switching group | P-value |
|-------------------------|-----------------|---------------------|---------|
| ΔSBP (mmHg)             | 0.9 ± 10.8      | -2.1 ± 13.0         | NS      |
| ΔDBP (mmHg)             | 1.5 ± 7.7       | -1.4 ± 8.2          | NS      |
| ΔHbA1c (%)              | -0.3 ± 0.4      | -0.1 ± 0.3          | <0.05   |
| ΔSerum K (mEq/L)        | 0.2 ± 0.4       | 0.1 ± 0.3           | NS      |
| ΔUA (mg/dL)             | -10.0 ± 1.0     | 0.2 ± 0.7           | <0.005  |
| ΔBMI (kg/m²)            | -0.5 ± 0.7      | -0.4 ± 0.6          | NS      |
| ΔBodyweight (kg)        | -1.4 ± 1.7      | -0.9 ± 1.5          | NS      |

Data presented as mean ± standard deviation. BMI, body mass index; DBP, diastolic blood pressure; K, potassium; NS, not significant; SBP, systolic blood pressure; UA, uric acid.

http://onlinelibrary.wiley.com/journal/jdi
difference between them. Furthermore, in the case of obtaining insufficient blood pressure control using ARB and CCB, we strongly suggest that an SGLT2 inhibitor should be used rather than thiazide diuretics as a next step in patients with hypertension complicated with type 2 diabetes. The improvement of blood pressure, as well as metabolism (e.g., glycemic control), would lead to suppressing macroangiopathy in the future. Needless to say, in order to demonstrate our hypothesis in the present study, prospective trials should be carried out in which thiazide diuretics or SGLT2 inhibitors are added to the existing antihypertensive therapy in patients with type 2 diabetes.

ACKNOWLEDGMENTS
The abstract of this report was presented at the 60th annual meeting of the Japan Diabetes Society (Nagoya) and the 117th regional meeting of the Japanese Society of Internal Medicine, and received a Young Investigator Award (Ube).

DISCLOSURE
HK has received honoraria for lectures, and received scholarship grants from Sanofi, Novo Nordisk, Lilly, Boehringer Ingelheim, MSD, Takeda, Ono Pharma, Daiichi Sankyo, Sumitomo Dainippon Pharma, Mitsubishi Tanabe Pharma, Pfizer, Kissei Pharma, AstraZeneca, Astellas, Novartis, Kowa, Chugai and Taisho Pharma. KK has been an advisor to, received honoraria for lectures from and received scholarship grants from Novo Nordisk Pharma, Sanwa Kagaku Kenkusho, Takeda, Taisho Pharmaceutical Co., Ltd, MSD, Kowa, Sumitomo Dainippon Pharma, Novartis, Mitsubishi Tanabe Pharma, AstraZeneca, Nippon Boehringer Ingelheim Co., Ltd, Chugai, Daiichi Sankyo, and Sanofi. The other authors declare no conflict of interest.

REFERENCES
1. Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension 1992; 19: 403–418.
2. Ray KK, Seshasai SR, Wijesuriya S, et al. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet 2009; 373: 1765–1772.
3. American Diabetes Association. Standards of medical care in diabetes–2013. Diabetes Care 2013; 36(Suppl 1): S11–S66.
4. Mansia G, De Backer G, Dominiczak A, et al. 2007 ESH-ESC Guidelines for the management of arterial hypertension: the task force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). Blood Press 2007; 16: 135–232.
5. Shimamoto K, Ando K, Fujita T, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2014). Hypertens Res 2014; 37: 253–390.
6. Yusuf S, Sleight P, Pogue J, et al. Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients. The Heart Outcomes Prevention Evaluation Study Investigators. N Engl J Med 2000; 342: 145–153.
7. Turnbull F, Neal B, Pfeffer M, et al. Blood pressure-dependent and independent effects of agents that inhibit the renin-angiotensin system. J Hypertens 2007; 25: 951–958.
8. UK Prospective Diabetes Study Group. Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998; 317: 713–720.
9. Porta M, Hainer JW, Jansson SO, et al. Exposure to candesartan during the first trimester of pregnancy in type 1 diabetes: experience from the placebo-controlled Diabetic RETinopathy Candesartan Trials. Diabetologia 2011; 54: 1298–1303.
10. Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001; 345: 851–860.
11. Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001; 345: 861–869.
12. Haller H, Ito S, Izzo Jr JL, et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011; 364: 907–917.
13. Makino H, Haneda M, Babazono T, et al. Prevention of transition from incipient to overt nephropathy with telmisartan in patients with type 2 diabetes. Diabetes Care 2007; 30: 1577–1578.
14. ALLHAT Officers and Coordinators for the ALLHAT Collaborative Research Group. The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: the Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). JAMA 2002; 288: 2981–2997.
15. Julius S, Kjeldsen SE, Weber M, et al. Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlopidine: the VALUE randomised trial. Lancet 2004; 363: 2022–2031.
16. Ogihara T, Nakao K, Fukui T, et al. Effects of candesartan compared with amlopidine in hypertensive patients with high cardiovascular risks: candesartan antihypertensive survival evaluation in Japan trial. Hypertension 2008; 51: 393–398.
17. Yui Y, Sumiyoshi T, Kodama K, et al. Comparison of nifedipine retard with angiotensin converting enzyme inhibitors in Japanese hypertensive patients with coronary artery disease: the Japan Multicenter Investigation for Cardiovascular Diseases-B (JMIC-B) randomized trial. Hypertens Res 2004; 27: 181–191.
18. Tuomilehto J, Rastenyte D, Birkenhager WH, et al. Effects of calcium-channel blockade in older patients with diabetes.
and systolic hypertension. Systolic Hypertension in Europe Trial Investigators. *N Engl J Med* 1999; 340: 677–684.

19. SHEP Cooperative Research Group. Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). *JAMA* 1991; 265: 3255–3264.

20. Patel A, MacMahon S, Chalmers J, *et al.* Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. *Lancet* 2007; 370: 829–840.

21. Zillich AJ, Garg J, Basu S, *et al.* Thiazide diuretics, potassium, and the development of diabetes: a quantitative review. *Hypertension* 2006; 48: 219–224.

22. Wing LM, Reid CM, Ryan P, *et al.* A comparison of outcomes with angiotensin-converting–enzyme inhibitors and diuretics for hypertension in the elderly. *N Engl J Med* 2003; 348: 583–592.

23. Wright EM, Turk E. The sodium/glucose cotransport family SLC5. *Pflugers Arch* 2004; 447: 510–518.

24. Imprialos KP, Sarafidis PA, Karagiannis AI. Sodium-glucose cotransporter-2 inhibitors and blood pressure decrease: a valuable effect of a novel antidiabetic class? *J Hypertens* 2015; 33: 2185–2197.

25. Kaku K, Inoue S, Matsuoka O, *et al.* Efficacy and safety of dapagliflozin as a monotherapy for type 2 diabetes mellitus in Japanese patients with inadequate glycaemic control: a phase II multicentre, randomized, double-blind, placebo-controlled trial. *Diabetes Obes Metab* 2013; 15: 432–440.

26. Stenlof K, Cefalu WT, Kim KA, *et al.* Efficacy and safety of canagliflozin monotherapy in subjects with type 2 diabetes mellitus inadequately controlled with diet and exercise. *Diabetes Obes Metab* 2013; 15: 372–382.

27. Schernthaner G, Gross JL, Rosenstock J, *et al.* Canagliflozin compared with sitagliptin for patients with type 2 diabetes who do not have adequate glycemic control with metformin plus sulfonylurea: a 52-week randomized trial. *Diabetes Care* 2013; 36: 2508–2515.

28. Cefalu WT, Leiter LA, Yoon KH, *et al.* Efficacy and safety of canagliflozin versus glimepiride in patients with type 2 diabetes inadequately controlled with metformin (CANTATA-SU): 52 week results from a randomised, double-blind, phase 3 non-inferiority trial. *Lancet* 2013; 382: 941–950.

29. Baker WL, Smyth LR, Riche DM, *et al.* Effects of sodium-glucose co-transporter 2 inhibitors on blood pressure: a systematic review and meta-analysis. *J Am Soc Hypertens* 2014; 8: e269.

30. Chino Y, Samukawa Y, Sakai S, *et al.* SGLT2 inhibitor lowers serum uric acid through alteration of uric acid transport activity in renal tubule by increased glycosuria. *Biopharm Drug Dispos* 2014; 35: 391–404.

31. Kimura G. Diuretic action of sodium-glucose cotransporter 2 inhibitors and its importance in the management of heart failure. *Circ J* 2016; 80: 2277–2281.